Johnson & Johnson — V-MIL Audit

Direct Defence Contracting & Procurement

Johnson & Johnson maintains direct operational presence in Israel through at least six subsidiaries, including J-C Health Care Ltd., ColBar LifeScience Ltd., Biosense Webster (Israel) Ltd., Intratech Medical Ltd., Orthospin Ltd., and Omrix Biopharmaceuticals Ltd. ¹². No verified contracts, tender awards, framework agreements, or memoranda of understanding between J&J (or its subsidiaries) and Israeli Ministry of Defence, Israel Defence Forces, Israel Prison Service, or Israel Border Police for defence equipment, weapons systems, or security infrastructure have been identified in public records ³⁴. J&J products may be present in IDF medical supply chains through standard Israeli Government Procurement Administration channels given J&J’s ubiquitous global presence, but no verified direct IDF Medical Corps contract has been publicly documented. No evidence has been found of J&J appearing in Israeli defence export directories (SIBAT), official defence exhibition catalogues, or defence procurement registries in a defence-supply capacity ⁴. No public evidence identified of J&J serving as prime contractor on any FMS case notification naming Apple as the channel for Israeli Ministry of Defense procurement.

Dual-Use Products & Tactical Variants

Through its wholly-owned subsidiary Omrix Biopharmaceuticals, J&J manufactures plasma-derived immunoglobulins in Israel, including biodefense products such as Vaccinia Immune Globulin (VIG/VIGIV) used as medical countermeasures against orthopoxvirus exposure — a dual-use category with both civilian and military/biodefense applications ⁵. No public evidence identified of any direct Israel Defence Forces, Israeli Ministry of Defence, or weapons-programme procurement contract for these Omrix products. J&J does not manufacture or market ruggedised, tactical, mil-spec, or defence-grade variants of its consumer, pharmaceutical, or MedTech products specifically for military application ⁴. J&J MedTech’s surgical platforms (Ottava, MONARCH, Velys, DePuy Synthes) are purpose-designed for civilian clinical environments and not marketed as military or tactical-grade systems. No publicly known export licence applications, end-user certificates, or government export control reviews specifically related to J&J sales to Israeli defence or security end-users have been identified in US DDTC, BIS, or EU/UK export control databases. No public evidence identified of J&J developing or marketing tactical variants of any consumer health product for military end-use.

Heavy Machinery, Construction & Infrastructure

Johnson & Johnson is a pharmaceutical, consumer health, and medical technology company; it does not manufacture heavy construction machinery, earthmoving equipment, armoured vehicles, or demolition equipment ⁴. No verified reports, photographic evidence, NGO investigations, or UN documentation placing J&J equipment, vehicles, or machinery in construction, maintenance, or demolition activity within Israeli settlements, the separation barrier, military installations, or occupied territories has been identified. No public evidence identified of J&J involvement in any heavy machinery supply to Israeli settlement infrastructure projects.

Supply Chain Integration with Defence Primes

No verified supply relationship where J&J provides components, sub-systems, raw materials, or specialist manufacturing services to Elbit Systems, Israel Aerospace Industries (IAI), Rafael Advanced Defense Systems, or Israel Military Industries has been identified ⁶⁴. No evidence of joint development programmes, co-production agreements, technology transfer arrangements, or licensed manufacturing agreements between J&J and Israeli defence firms has been found. No public evidence identified of J&J supplying raw materials, intermediates, or specialty chemicals to any Israeli defence prime contractor.

Logistical Sustainment & Base Services

Through subsidiary Omrix Biopharmaceuticals Ltd. (acquired 2005), J&J operated a blood bank at Sheba Medical Center (Tel Hashomer) until 2021 ⁷. Sheba Medical Center is Israel’s largest hospital and serves as a major military/combat trauma centre treating IDF personnel. No verified contracts to provide catering, transport, fuel supply, waste management, facilities maintenance, or telecommunications services to IDF bases, military training facilities, detention centres, or security installations have been identified. J&J’s business lines do not encompass these service categories. No public evidence identified of J&J providing logistical support to any IDF base or military installation beyond the historical blood bank operations at Sheba.

Munitions, Weapons Systems & Strategic Platforms

J&J has no verified role as a prime contractor or licensed manufacturer of small arms, artillery systems, armoured vehicles, tactical drones, naval vessels, or other lethal platforms ⁴. No evidence of J&J involvement in manufacture, integration, maintenance, or supply of components for Iron Dome, David’s Sling, Arrow, F-35, Merkava tanks, or Sa’ar-class warships has been found. No evidence of J&J supplying ammunition, explosive ordnance, chemical propellants, warhead components, or munitions precursor materials to Israeli defence end-users has been identified. No public evidence identified of J&J involvement in any weapons system, munitions manufacturing, or strategic platform supply chain.

Export Licensing, Regulatory & Legal History

No publicly known government decisions to grant, deny, suspend, or revoke export licences for J&J products to Israeli military or security end-users in US, EU, or UK jurisdictions have been identified. No investigations, citations, or enforcement actions related to J&J’s compliance with arms embargoes, export control regimes, or sanctions affecting defence trade with Israel have been identified in BIS, OFAC, DDTC, or equivalent EU/UK enforcement databases ⁴. No court proceedings, judicial reviews, or legal challenges specifically brought against J&J or against governments regarding J&J’s defence supply relationship with Israel have been found. No public evidence identified of any export licence denial or enforcement action against J&J related to Israeli military end-users.

Civil Society Scrutiny & Documented Investigations

J&J is not listed among the 158 companies in the UN Human Rights Council database of business enterprises involved in Israeli settlement activity (2020, 2023, 2025 iterations) ⁸. J&J is not included in the June 2024 PAX “Companies Arming Israel and Their Financiers” report, which focuses on 6 major arms producers ⁶. J&J does not appear in the Who Profits Research Center database of companies operating in Israeli settlements ³. J&J is not specifically flagged in the American Friends Service Committee “Investigate” database for weapons, military systems, or lethal technology supply to Israeli forces ⁴. The Special Rapporteur’s July 2025 report (A/HRC/59/23) does not specifically name Johnson & Johnson in its company listings, which focus on arms, energy, banking, and tech sectors ⁹.

Multiple BDS campaigns cite J&J as a boycott target, but the publicly cited grounds are “direct involvement in the Israeli economy” through commercial operations, not defence or military supply. BDS India, BDS Coalition Canada (BDS Shame List), and Disoccupied.com all list J&J under commercial boycott targets ¹⁰¹¹¹². No pension funds or sovereign wealth funds have divested from J&J specifically citing Israeli defence or settlement activities. Norway’s Government Pension Fund Global exclusion list does not include J&J ¹³.

J&J Board member Marillyn A. Hewson (joined 2019) is former Chairman/CEO of Lockheed Martin (2013-2021). Lockheed Martin is a primary supplier of F-35 components and weapons systems to Israel ¹⁴. J&J Board member Dr. Nadja West (joined 2020) is a retired US Army Lieutenant General and former Army Surgeon General (2015-2019), overseeing military healthcare operations ¹⁵. No public statements, policy changes, contract terminations, or end-use monitoring commitments specifically addressing civil society pressure regarding Israeli defence supply chain have been identified. No public evidence identified of any institutional investor divesting from J&J based on defence-related concerns.

End Notes